Sapporo City General Hospital

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• IgA nephropathy3 trials
• Multiple myeloma2 trials
• Fibromyalgia1 trial
• Macular degeneration1 trial
• Rheumatoid arthritis1 trial

Phase

• Phase 35 trials
• Phase 22 trials
• Phase 11 trial

Status

• Completed4 trials
• Active, not recruiting2 trials
• Recruiting2 trials

Lead sponsor

• Janssen Research & Development, LLC2 trials
• Alfasigma S.p.A.1 trial
• Alpine Immune Sciences Inc, A Subsidiary of Vertex1 trial
• argenx1 trial
• Bayer1 trial
• and 2 more

Running trials

• Recruiting

  A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

  NCT07773727· Phase 2· argenx· Source

  Contact: Mamiko Shimamoto, MD (principal investigator)

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source

• Active, not recruiting

  A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

  NCT06208150· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• IgA nephropathy1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Completed

  A Clinical Study of ONO-1110 in Patients With Fibromyalgia

  NCT06752590· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Completed

  A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

  NCT05174221· Phase 1· Takeda· Source

• Completed

  Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

  NCT04423718· Phase 3· Bayer· Source

• Completed

  Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

  NCT03025308· Phase 3· Alfasigma S.p.A.· Source